Below are Citigroup’s estimates for the percentage of each Big Pharma’s 2010 corporate-wide sales that come from US branded prescription drugs. NVS, at 16%, is the lowest of any Big Pharma. (I think Citi’s 16% figure is a little too low and prefer my own estimate of 20% in #msg-49251301, but this is splitting hairs.)
Note that all of these companies except BMY and NVO have non-pharma business segments. (MRK’s % of sales from US pharma was much higher before it merged with SGP; PFE’s % was higher before it merged with WYE.)